Hybridoma technology for the generation of monoclonal antibodies

85Citations
Citations of this article
220Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies (mAbs). Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. With the establishment of mAb humanization and with the development of transgenic-humanized mice, hybridoma technology has opened new avenues for effectively generating humanized or fully human mAbs as therapeutics. In this chapter, an overview of hybridoma technology and the laboratory procedures used routinely for hybridoma generation are discussed and detailed in the following sections: cell fusion for hybridoma generation, antibody screening and characterization, hybridoma subcloning and mAb isotyping, as well as production of mAbs from hybridoma cells. © 2012 Springer Science+Business Media, LLC.

Cite

CITATION STYLE

APA

Zhang, C. (2012). Hybridoma technology for the generation of monoclonal antibodies. Methods in Molecular Biology. https://doi.org/10.1007/978-1-61779-931-0_7

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free